News

MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD),

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference. A recording of the fireside chat will be

MENLO PARK, Calif.— November 17, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular

Observational studies leverage machine learning to create Mind.PxTM, a test that prospectively predicts biologic class response for individual psoriasis patients with high Positive Predictive Values (PPV) SAN DIEGO, CA – November 16, 2021 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,  has announced

Sight Sciences Reports Third Quarter 2021 Financial Results   MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended September 30, 2021.   Recent Business

MENLO PARK, Calif.— November 10, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced that the Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) authorizing the Company to conduct a clinical study to

HAYWARD, Calif., November 8, 2021 – Potrero Medical, innovator of the Accuryn Monitoring System, announced the launch of its newest software App for the Accuryn™ Monitor and AccuTab™. The Accuryn Monitoring System includes a revolutionary sensor-integrated foley catheter that provides real-time, actionable information to healthcare providers, enabling them to take important, earlier steps to prevent

Series of Presentations Highlights Company’s Novel Intra-aortic Pump that Treats Patients with Heart Failure and Worsening Renal Function HOUSTON, TX – NOVEMBER 2, 2021 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the schedule of presentations to be featured at the annual Transcatheter

Presentation highlights return to work, ADL, and disability improvement in 246 subjects with 12-month follow-up. SAN CARLOS, Calif., November 2, 2021, / OrthoSpineNews / – Empirical Spine, Inc., a Silicon-Valley based medical technology company, announced today that data from the IDE study of the company’s LimiFlex Tension Band for patients suffering from degenerative spondylolisthesis with lumbar spinal

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time /